6533b824fe1ef96bd1280b80
RESEARCH PRODUCT
Kelfiprim, a new sulpha-trimethoprim combination, versus cotrimoxazole, in the treatment of urinary tract infections: a multicentre, double-blind trial.
P. LarckerM. LamartinaF. PirozziE. PisaniU. RotoloF. PiaiaF. RoccoMichele Pavone-macalusoD. Mellonisubject
NephrologyMalemedicine.medical_specialtySulfamethoxazoleUrologyUrinary systemUrineGastroenterologyLoading doseTrimethoprimDouble blindDouble-Blind MethodInternal medicineSulfanilamidesTrimethoprim Sulfamethoxazole Drug CombinationmedicineHumansClinical Trials as Topicbusiness.industrySulfaleneTrimethoprimSurgeryDrug CombinationsUrinary Tract InfectionsFemalebusinessmedicine.drugdescription
A new combination of trimethoprim with a sulphonamide, named Kelfiprim, differs from cotrimoxazole in that: a) the sulpha drug is sulphamethopyrazine instead of sulphamethoxazole; b) the trimethoprim to sulpha ratio is 5:4 instead of 1:5;c) the presence of a long-acting sulphonamide allows the administration of a daily dose of one capsule, following an initial loading dose of two capsules; d) a reduced amount of trimethoprim is given, as compared to cotrimoxazole, without any decrease of efficacy. Kelfiprim [KP] was compared to contrimoxazole [Co] in a multicentre double blind trial. Sixty four patients suffering from acute and chronic infections of the upper and lower urinary tract entered the study. Urine sterilisation and clinical improvement without relapses showed no differences from the two treatment groups. Tolerance was excellent except in two patients, one treated with KP and the other treated with Co, who showed a transient exanthema.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1982-02-01 | Urological research |